Regeneron Pharmaceuticals appears to be maintaining a substantial presence in the biotech industry. The pharmaceutical giant has secured FDA approval along with Sanofi for Dupixent treating CSU, and garneredFDA Priority Review for EYLEA HD Injection. However, despite these strides, the firm’s EYLEA HD extended dosing application was dismissed, leaving the existing 16-week program approved. Amid fluctuating stock prices, with prominent financial institutions both acquiring and disposing of shares, the company remains an enticing prospect for investors. These transactions include Evergreen Capital Management acquiring 3,030 shares and GKV Capital Management purchasing 3,835 shares, while Rockefeller Capital Management sold 3,260 shares. It's worth noting that an ongoing lawsuit is encouraging shareholders to contact the Shareholders Foundation. Regulatory and legal challenges persist, including issues over Eylea pricing practices. Despite price target cuts to $917.00 and $150.00 by Goldman Sachs Group and Canaccord Genuity Group respectively, some experts still see REGN shares as profitable investments, maintaining positions of confidence.
Regeneron Pharmaceuticals REGN News Analytics from Tue, 14 Jan 2025 08:00:00 GMT to Sat, 19 Apr 2025 15:25:07 GMT -
Rating 2
- Innovation 0
- Information 8
- Rumor 6
